Clinical trial
Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric…
NCT00384878 · Far Eastern Memorial Hospital, Other · Unknown status
Key facts
| NCT number | NCT00384878 |
|---|---|
| Title | Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer |
| Official title | A Phase II Study of Cetuximab Plus P-HDFL (Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) for the First-Line Treatment of Advanced Gastric Cancer |
| Lead sponsor | Far Eastern Memorial Hospital, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomach Neoplasms |
| Intervention type | Drug |
| Interventions | Cetuximab, Cisplatin, 5-Fluorouracil, Leucovorin |
| Enrollment | 35 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2007 |
| First posted | Oct 6, 2006 |
| Last update posted | Feb 9, 2009 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: